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LINICAL INVESTIGATION Breast
THE RISK OF EARLY AND LATE LUNG SEQUELAE AFTER CONFORMAL
RADIOTHERAPY IN BREAST CANCER PATIENTS
ZSUZSANNA KAHÁN, M.D., PH.D.,* MELINDA CSENKI, M.D.,* ZOLTÁN VARGA, M.SC.,*
ELEMÉR SZIL, PH.D.,* ADRIENN CSERHÁTI, M.D.,* ATTILA BALOGH, M.D., PH.D.,†
ZSÓFIA GYULAI, M.D., PH.D.,† YVETTE MÁNDI, M.D., PH.D.,† KRISZTINA BODA, PH.D.,‡ AND
LÁSZLÓ THURZÓ, M.D., PH.D.*
Departments of *Oncotherapy, †Microbiology and Immunobiology, and ‡Medical Informatics, University of Szeged,
Szeged, Hungary
Purpose: To study the risks of early and late radiogenic lung damage in breast cancer patients after conformal
radiotherapy.
Methods and Materials: Radiogenic lung sequelae were assessed prospectively in 119 patients by means of clinical
signs, radiologic abnormalities, and the mean density change (MDC) of the irradiated lung on CT.
Results: Significant positive associations were detected between the development of lung abnormalities 3 months
or 1 year after the radiotherapy and the age of the patient, the ipsilateral mean lung dose (MLD), the radiation
dose to 25% of the ipsilateral lung (D25%) and the volume of the ipsilateral lung receiving 20 Gy (V20 Gy). The
irradiation of the axillary and supraclavicular lymph nodes favored the development of pneumonitis but not that
of fibrosis. No relation was found between the preradiotherapy plasma TGF- level and the presence of
radiogenic lung damage. At both time points, MDC was strongly related to age. Significant positive associations were
demonstrated between the risks of pneumonitis or fibrosis and the age of the patient, MLD, D25%, and V20 Gy.
A synergistic effect of MLD, D25%, and V20 Gy with age in patients older than 59 years is suggested.
Conclusion: Our analyses indicate that the risks of early and late radiogenic lung sequelae are strongly related
to the age of the patient, the volume of the irradiated lung, and the dose to it. © 2007 Elsevier Inc.
Breast cancer, Conformal radiotherapy, Lung density, Radiation pneumonitis, Radiogenic lung fibrosis, Smok-
ing, TGF-.
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AINTRODUCTION
s a standard form of treatment after breast-conserving
urgery, adjuvant radiotherapy is administered in a sig-
ificant proportion of the patients and contributes to the
ecreasing mortality rate among the affected population
1, 2). Accordingly, it is vital that the frequency, extent,
nd severity of the side effects should be kept as low as
ossible.
The reported incidence of radiation-induced lung injury
n breast cancer in prospective studies varies between 4.5%
nd 63% (3–8) and in retrospective studies between 0.9%
nd 30% (9–11). Early radiation-induced symptoms arise
ithin 6 months after the completion of radiotherapy and
ay later progress to a chronic fibrotic status (12, 13). In
lder age, the irradiation of a larger lung volume and a
igher mean lung dose (MLD) have been found to be risk
actors for the occurrence of radiogenic lung damage (11,
4). The risk may be reduced through the use of conformal
Reprint requests to: Zsuzsanna Kahán, M.D., Ph.D. Department
f Oncotherapy, University of Szeged, Korányi fasor 12, H-6720
zeged, Hungary; Tel: (36) 62-545406; Fax: (36) 62-545922;
-mail: kahan@onko.szote.u-szeged.hu
673adiotherapy (15, 16), and under such conditions, the low
ate of lung complications may be more dependent on
atient-related variables (6).
Transforming growth factor (TGF)- has been implicated
s a key cytokine in the development of the radiation-related
njury of various normal tissues, including the lung (17–24).
lthough the autocrine and paracrine actions of TGF- are
ell established, the endocrine effects are vague. The ex-
ression of TGF- may be induced by radiation (17, 18).
mong other factors, its circulating level may reflect indi-
idual radiation sensitivity (18, 21, 23, 24).
We set out to perform a prospective analysis of the risks
f early and late radiogenic lung damage in early breast
ancer patients after conformal radiotherapy. The primary
bjective was to study radiogenic lung damage in relation to
he various patient- and treatment-associated characteristics.
he secondary objective was to investigate whether the
lasma TGF- level before or after the radiotherapy might
Conflict of interest: none.
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674 I. J. Radiation Oncology ● Biology ● Physics Volume 68, Number 3, 2007erve to predict early or late radiogenic lung damage. We
eport here the results of this clinical study of 119 patients.
METHODS AND MATERIALS
The study had been approved by the Institutional Review Board
f the University of Szeged, and all enrolled patients gave their
ritten informed consent before being registered as participating
n the study.
tudy population
Between November 2001 and August 2004, 119 patients after
urative surgery for breast cancer who required radiotherapy were
ecruited at our department. Systemic treatment was administered
n accordance with the institutional guidelines. Perioperative che-
otherapy was completed 4 weeks or more before the radiother-
py, and adjuvant hormonal therapy (tamoxifen or anastrozole), if
ecessary, was given simultaneously with radiotherapy. Patients
ith prior malignancy, pulmonary or autoimmune disease, any
ther significant health problem, or who were on glucocorticoid
herapy were excluded. Data on smoking habits were collected,
ith the participants categorized as past or present smokers or
onsmokers.
adiotherapy
CT-based three-dimensional treatment planning was performed
or each patient. All patients were irradiated in the supine position,
ith both arms elevated above the head. The target volume and
rgans at risk (OARs) were contoured on the CT slices in a
ucletron TMS radiotherapy planning system (Nucletron B.V.,
eenendaal, The Netherlands) according to the local protocol,
ased on the literature (5, 8, 16). Local (operated breast or chest
all) or locoregional (the former together with the coverage of any
f the following regions: axillary, supraclavicular, and internal
ammary lymph nodes [IMNs]) radiotherapy was chosen in ac-
ordance with the local protocol. For local irradiation we used two
angential photon beams, for the treatment of the IMNs a deep
blique field, and for the coverage of axillary and supraclavicular
ymph nodes an anterior photon beam. Conformal radiotherapy
as delivered by multiple 6/15-MV photon fields to the remaining
reast parenchyma/chest wall and to the lymph nodes, if indicated,
t a dose of 25  1.8–2 Gy; the tumor bed was irradiated with
ither 6-MV photon or 8–15-MeV electron fields when necessary.
rescribed OAR dose constraints were based on literature data (9,
6, 25–27) as follows: central lung distance (CLD) 3 cm, and
LD20 Gy. We defined the percentage volume of the ipsilateral
ung receiving at least 20 Gy (V20 Gy) as 25%, and endeavored
o keep the volume of the ipsilateral lung irradiated with 25 Gy or
ore, under 25% (D25%  25 Gy) as optimal thresholds. A
aximum heart distance of 2 cm and a maximum heart volume
eceiving at least 25 Gy of 10% were also attempted.
The radiation dose to the contralateral breast was recorded.
adiotherapy was delivered with a linear accelerator (Mevatron
DS-2; Siemens AG, Berlin, Germany) in five fractions per week.
GF- determinations
Blood samples were collected from each patient as follows: on
he day of the commencement of the radiotherapy, on the last day
f irradiation of the breast/chest wall or lymph node regions, and
months later. Whole blood (6 mL) was drawn (without placing rtourniquet on the patient’s arm) into tubes containing 7.5%
3EDTA and immediately transferred on ice to the laboratory.
Plasma TGF- levels were measured with a Quantikine ELISA
it (R&D Systems, Minneapolis, MN) according to the manufac-
urer’s instructions. The limiting sensitivity of the test was 7
g/mL.
valuation of radiogenic lung damage
The patients were regularly seen at 3-month follow-up visits. At
months and 1 year after the completion of radiotherapy, CT
xaminations were performed. The CT scans were compared with
hose provided for radiotherapy planning purposes. Inflammatory
r fibrotic abnormalities were diagnosed according to the accepted
riteria, that is, increased density, hazy opacity, strandlike densi-
ies, or an onset of shrinkage for pneumonitis; thickened interlob-
lar septae, subpleural strands, and fibrous intraparenchymal
trands for fibrosis.
Early and late radiogenic lung damage was evaluated according
o the Common Toxicity Criteria version 2.0. (The categories
pneumonitis of Grade 1” and “lung fibrosis of Grade 1” were used
hen radiographic changes occurred with or without pulmonary
ymptoms not requiring steroids; none of the patients in this study
eveloped Grade 2 pneumonitis or fibrosis requiring steroids or
iuretics.)
Lung density measurements were performed on each set of CT
cans of a series of 94 patients, using an improved method based
n that of Wennberg et al. (5). In 19 cases, at least one of the sets
f CT scans was not available in a digital format appropriate for
ensity measurements, and in 6 cases, CT was not performed 1
ear after the radiotherapy because of disease progression (n  4),
udden death (n 1), or lack of patient compliance (n 1). In the
entral slice (at the level of the left heart ventricle), lines were
rawn between the edge of the sternum and the midheight of the
psilateral chest wall on both sides, and mean lung density was
easured in the areas defined by the lines and the chest wall (Fig. 1).
n 48 patients who received locoregional irradiation, mean lung
ensity was additionally measured in the entire area of both lungs
n the apical slice at the level of the superior aspect of the head of
he clavicle (Fig. 1). Rarely found inflammatory or fibrotic lesions
n the postradiotherapy CT scans were excluded from the region
f interest. To correct for lung density differences due to breathing,
he contralateral mean lung density value was subtracted from that
f the ipsilateral lung. The differences between the corrected
psilateral lung densities at 3 months or 1 year after and before the
adiotherapy were taken as the mean lung density changes at the
evel of the left heart ventricle (MDCLHV) and the head of the clavicle
MDCHC).
tatistical analysis
The various patient- and radiotherapy-related characteristics
ere examined according to the presence or the absence of Grade
pneumonitis or fibrosis or the change in lung density after the
adiotherapy by univariate statistical methods: for the continuous
ariables Student’s t test, and for the categorical variables the
hi-square test, followed by Fisher’s exact test were utilized. The
hanges in MDCLHV and MDCHC or the TGF  levels were tested
y repeated-measures analysis of variance. Spearman’s coefficient
f correlation was computed to examine the relationship between
he variables. Multiple linear regression was used to examine the
oint effect of the potential risk factors on lung density. Logistic
egression models were applied to examine the potential risk
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675Radiation lung sequelae in breast cancer patients ● Z. KAHÁN et al.actors for the occurrence of Grade 1 pneumonitis or fibrosis: first,
inary univariate logistic regression models used separately, fol-
owed by multivariate logistic regression models to examine the
oint effects and the interactions. A stepwise procedure was used
ith a likelihood ratio test. Statistical analysis was performed with
PSS 11.0 for Windows and Statistica 6.1 for Windows (SPSS
nc., Chicago, IL).
RESULTS
The data on 119 patients were analyzed. The mean (
E) age of the study population was 58.1 1.0 (28.2–80.4)
ears; 34% of the patients had undergone mastectomy, and
6% tumor excision with sentinel lymph node biopsy and/or
xillary lymph node dissection. The vast majority (96%) of
he tumors were invasive, and two-thirds were invasive
uctal cancers. Sixty-four (54%) were node-negative. Forty-
wo patients (35%) were past or present smokers. The
istribution of the irradiated volumes and the resulting data
oncerning the dose to the lung are presented in Table 1.
Forty-four patients (37%) were categorized as having
rade 1 pneumonitis, but only 9 (7.5%) of them exhibited
linical symptoms. The occurrence of early lung damage
as compared with the various patient- and radiotherapy-
elated characteristics (Table 2). Significant associations
ere found between the development of pneumonitis and
he age of the patient (p  0.012), MLD (p  0.003), V20
y (p  0.005), and D25% (p  0.001). No difference in the
Fig. 1. Evaluation of lung density in the computed tomog
superior aspect of the head of the clavicle (b). Mean l
outlined on both sides, and for the accurate assessment of
by that on the contralateral side.
Table 1. Parameters reflecting the radiation dose to t
Target volume
Breast (n  52)
Chest wall (n  3)
Breast/chest wall  supraclavicular  axillary lymph
nodes (n  3)
Breast/chest wall  supraclavicular  axillary  inte
mammary lymph nodes (n  61)
Abbreviation: MLD  mean lung dose.
* Volume of the ipsilateral lung receiving 20 Gy.
† Dose to 25% of the volume of the ipsilateral lung.LD measures was found between the patients with or
ithout early radiogenic lung changes. Radiotherapy of the
upraclavicular and axillary lymph nodes favored Grade 1
neumonitis (p  0.022), but no such effect was found
hen the analysis was performed according to the inclusion
r exclusion of the IMNs in the PTV. No significant differ-
nce was found in the occurrence of Grade 1 pneumonitis
ccording to the type of the surgery. A past or present
istory of smoking was associated with a lower rate of early
adiogenic lung damage (p  0.028) (Table 2). Among the
onsmoker patients, 10% developed symptomatic pneumo-
itis and 35% exhibited radiologic changes; the correspond-
ng rates in the group of past or present smokers were 2%
nd 19%, respectively.
Lung density measurements were also available at 3 and
2 months after radiotherapy in 94 cases at the level of the
eft heart ventricle (MDCLHV) and in 48 cases with locore-
ional irradiation at the level of the head of the clavicle
MDCHC), as well. The MDCLHV values were increased
ignificantly 3 months after the radiotherapy in patients with
neumonitis as compared with those without pneumonitis.
o such difference was found for MDCHC (Table 2).
Late radiation lung sequelae could be studied in 113
atients; 40 (35.4%) developed apparent minor fibrotic
hanges corresponding to Grade 1 fibrosis on CT scan,
cquired 1 year after the completion of the radiotherapy, but
one had clinical symptoms or needed medical treatment.
slices at the levels of the left heart ventricle (a) and the
nsity was measured in the region of interest (ROI) as
ensity changes, the ipsilateral lung density was corrected
ilateral lung after local or locoregional radiotherapy
MLD (Gy) V20 Gy* (%) D25%† (Gy)
8.8 0.4 16.2 0.8 7.2 1.1
8.7 1.5 15.5 3.2 5.3 0.8
17.1 1.5 33.6 4.1 35.6 6.1
17.1 0.4 36.7 1 34.1 1raphy
ung de
lung dhe ips
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676 I. J. Radiation Oncology ● Biology ● Physics Volume 68, Number 3, 2007he presence of inflammatory changes at 3 months was
trongly correlated with that of fibrotic abnormalities at 1
ear (r  0.733, p  0.0001). The inflammatory CT lesions
etected at 3 months after the radiotherapy had disappeared
months later in 6 patients, and 3 patients developed new
brotic lesions 1 year after the radiotherapy without having
ad early lung changes before that. The associations be-
ween the radiogenic pulmonary changes 1 year after the
rradiation and the data relating to the patient or the radio-
herapy are included in Table 3. Significant associations
ere found between the development of fibrosis and the age
f the patient (p  0.006), MLD (p  0.017), V20 Gy (p 
.034), and D25% (p  0.004). We examined the risk of
brosis depending on lung density changes with logistic
egression. Significant associations were found between the
evelopment of fibrotic abnormalities and both MDCLHV
odds ratio [OR]  1.019, for every 1.0 unit increase; 95%
I, 1.01–1.028; p  0.0001) and MDCHC (OR  1.013, for
very 1.0 unit increase; 95% CI, 1.001–1.026; p  0.041)
easured 3 months after the radiotherapy. Significant asso-
iations were not found between the development of fibrotic
hanges and CLD, irradiation of the regional lymph nodes,
Table 2. Patient-related and therapy-related features among
patients with or without Grade 1 pneumonitis
No change
Grade 1
pneumonitis p
ge (years) 56.2 1.3 61.5 1.5 0.012*
ype of surgery
Excision 51 (66%) 26 (34%) 0.427†
Mastectomy 24 (57%) 18 (43%)
moking
Nonsmoker 42 (55%) 35 (45%) 0.010†
Past or present smoker 33 (79%) 9 (21%)
T of the supraclavicular
and axillary nodes
Yes 34 (53%) 30 (47%) 0.022†
No 41 (75%) 14 (25%)
T of the internal
mammary nodes
Yes 34 (56%) 27 (44%) 0.128†
No 41 (71%) 17 (29%)
LD (Gy) 12.2 0.6 15.0 0.7 0.003*
20 Gy (%) 24.8 1.5 31.1 1.6 0.005*
25% (Gy) 18.1 1.8 27.7 2.2 0.001*
LD (cm) 2.7 0.1 2.9 0.1 0.202*
DCLHV (HU) at 3
months
67.0 8.3 122.4 14.3 0.001*
DCHC (HU) at 3
months
47.7 10.9 65.3 13.0 0.369*
Abbreviations: RT  radiotherapy; MLD  mean lung dose;
20Gy  Volume of the ipsilateral lung receiving 20 Gy; D25% 
he dose at least delivered to 25% of the volume of the ipsilateral
ung; CLD  central lung distance; MDCLHV  mean density
hange of the irradiated lung at the level of the left heart ventricle;
DCHC  mean density change of the irradiated lung at the level
f the head of the clavicle.
* Student’s t-test.
† Fisher’s exact test.he type of surgery, or smoking habit. The MDCLHV valuesere increased significantly 1 year after the radiotherapy in
hose patients who displayed fibrotic lung changes. No such
ifference was found for MDCHC (Table 3). MDCLHV and
DCHC were significantly reduced at 1 year compared with
months after the radiotherapy (p  0.001).
Radiogenic lung damage was quantitatively analyzed via
he lung density changes in relation to the patient- and
adiotherapy-related parameters. MDCLHV at 3 months was
orrelated with age (r  0.2, p  0.046) and MDCLHV at 1
ear (r  0.564, p  0.001), but not with MLD, V20 Gy,
25%, or CLD. MDCLHV at 1 year, however, in addition to
ge (r  0.278, p  0.007), was significantly correlated
ith MLD (r  0.206, p  0.047), V20 Gy (r  0.214, p 
.039), and D25% (r  0.214, p  0.039) but not with the
ther parameters. The MDCHC values at 3 months and 1
ear correlated significantly (r  0.521, p  0.001) but
ere not related to any of the other parameters.
The initial plasma TGF- levels and those at the termi-
ation of radiotherapy were not related to radiogenic lung
amage at 3 months or 1 year after the radiotherapy. We
ound correlations between the TGF- level and MDCLHV
r  0.264, p  0.029) and MDCHC (r  0.622, p  0.002)
months after the radiotherapy. Those patients who devel-
ped symptomatic pneumonitis had significantly higher
GF- levels 3 months after the radiotherapy than the
atients with no CT changes (p 0.006) or the patients who
eveloped asymptomatic CT abnormalities (p  0.028)
Fig. 2). The plasma TGF- level was not associated with
moking.
To estimate the risk of pneumonitis or fibrosis, the effects
Table 3. Patient-related and therapy-related features among
patients with or without Grade 1 fibrosis
No fibrosis Fibrosis p
ge (years) 56.7 1.2 62.4 1.5 0.006*
ype of surgery
Excision 46 (63%) 27 (37%) 0.685†
Mastectomy 27 (68%) 13 (32%)
moking
Nonsmoker 43 (59%) 30 (41%) 0.103†
Past or present smoker 30 (75%) 10 (25%)
T of the supraclavicular
and axillary nodes
Yes 33 (57%) 25 (43%) 0.115†
No 40 (73%) 15 (27%)
T of the internal
mammary nodes
Yes 33 (60%) 22 (40%) 0.333†
No 40 (69%) 18 (31%)
LD (Gy) 12.2 0.6 14.5 0.7 0.017*
20 Gy (%) 24.7 1.4 29.8 1.8 0.034*
25% (Gy) 17.9 1.7 26.2 2.4 0.004*
LD (cm) 2.7 0.1 2.8 0.1 0.412*
DCLHV (HU) at 1 year 31.5 9.76 95.8 17.91 0.0001*
DCHC (HU) at 1 year 25.8 6.0 35.2 9.9 0.38*
Abbreviations as in Table 2.
* Student’s t-test.
† Fisher’s exact test.
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677Radiation lung sequelae in breast cancer patients ● Z. KAHÁN et al.f the age of the patient, MLD, V20 Gy, D25%, and irradiation
f the supraclavicular and axillary lymph nodes were first
tudied in separate univariate logistic regression models,
esulting in crude odds ratios (Tables 4 and 5). The risk of
rade 1 pneumonitis or fibrosis increased with the age of
he patient. Significant positive associations were demon-
trated between the risks of pneumonitis or fibrosis and
LD, D25%, and V20 Gy. Irradiation of the axillary and
upraclavicular lymph nodes increased the risk of pneumo-
itis but did not significantly influence the risk of Grade 1
brosis (Tables 4 and 5). Multivariate logistic regression
nalysis was applied, including one of the dose parameters
MLD, D25% and V20 Gy) or the irradiation of the axillary
nd supraclavicular lymph nodes and age in separate models
o examine their effects and interactions using a stepwise
lgorithm. This strategy was followed because of the strong
orrelation between the variables related to irradiation of the
ung. The effects of the age, the irradiation of the axillary
nd supraclavicular lymph nodes, and the parameters indi-
ating the radiation dose to the lung remained significant in
ach case, but their interaction with age was not significant.
ig. 2. Circulating TGF- level in patients with or without radia-
ion lung damage before (TGF-0), at the end of (TGF-1) and 3
onths after the radiotherapy (TGF-2).
Table 4. OR and 95% CI for pneumoniti
radiotherapy-
Crude
Variable OR 95% CI
Age 1.05 1.01–1.09
MLD 1.13 1.04–1.22
V20 Gy* 1.04 1.01–1.08
D25%† 1.04 1.02–1.07
RTsupra-axilla‡ 2.59 1.18–5.64
Abbreviations: CI  confidence interval; M
For continuous variables, OR indicates the
* Volume of the ipsilateral lung receiving 2
† Dose to 25% of the volume of the ipsilate
‡ Irradiation of the supraclavicular and axillary lymhus, all the dose parameters and the irradiation of the
xillary and supraclavicular lymph nodes, when adjusted for
ge, predicted the occurrence of pneumonitis and fibrosis
ut did not show synergism in the overall population. The
djusted odds ratios are shown in Tables 4 and 5.
We followed the approach of Gagliardi et al. (11) in
esting whether use of the median age of the study popula-
ion as a threshold would better identify patients at high risk
f early lung complications. Patients older than 59.33 years
ad OR  2.48 (95% confidence interval [CI], 1.15–5.35;
 0.018) and OR  3.34 (95% CI, 1.47–7.60; p  0.004)
or a higher risk of radiation pneumonitis or fibrosis, re-
pectively. When this age limit was combined with MLD or
he irradiation of the axillary and supraclavicular lymph
odes, significant interactions were found for both pneumo-
itis (OR  1.27, for every 1.0-Gy increase, 95% CI,
.11–1.46; p  0.0001 for MLD, and OR  7.65, 95% CI,
.98–19.62; p  0.0001 for inclusion of the lymph nodes
nto the irradiated volume, respectively) and Grade 1 fibro-
is (OR  1.12, for every 1.0-Gy increase, 95% CI, 1.06–
.19; p  0.0001 for MLD and OR  6.43; 95% CI,
.53–16.37; p  0.0001 for inclusion of the lymph nodes
nto the irradiated volume, respectively). When MLD was
eplaced in the model by either V20 Gy or D25%, the results
ere very similar (data not shown).
DISCUSSION
We found a 37% incidence of radiation Grade 1 pneu-
onitis and a 35.5% incidence of Grade 1 radiation fibrosis
n breast cancer patients after conformal adjuvant radiother-
py. Only nine of the patients with early lung reactions
xhibited clinical symptoms, and no patient had respiratory
roblems due to lung fibrosis. The strongest risk predictor
or radiation lung sequelae was the age of the patient. The
arameters reflecting the dose to and the volume of the
rradiated lung were associated with the risk of pulmonary
omplications and displayed synergism with the age in
atients 59 years old. In patients with pneumonitis, ele-
regard to the age of the patient and the
parameters
Adjusted for age
OR 95% CI p
5
4 1.16 1.07–1.27 0.001
8 1.06 1.02–1.10 0.002
2 1.05 1.02–1.08 0.0001
5 3.13 1.38–7.10 0.006
mean lung dose; OR  odds ratio.
r every one–unit increase in that variable.
g.s with
related
p
0.01
0.00
0.00
0.00
0.01
LD 
risk fo
0 Gy.
ral lunph nodes.
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678 I. J. Radiation Oncology ● Biology ● Physics Volume 68, Number 3, 2007ated circulating levels of TGF- were found 3 months after
he radiotherapy.
Radiation-induced lung injury, both early as radiation
neumonitis and late as radiation fibrosis, has been studied
xtensively. The incidence of radiation pneumonitis varies
etween 0.9 and 80% (3, 4, 7–10, 28–30) and is obviously
essened by the performance of conformal radiotherapy (4,
, 8, 15, 16). The frequencies of pneumonitis after confor-
al radiotherapy in other series were 0.9–11% (3), 8% (8),
0–26% (6), 23% (5), 29% (11), and 47% (4). Radiogenic
brosis was diagnosed in 6.4% (8), 22.1% (30), and 87% (7)
f patients in other studies. One reason for such a wide
ange of incidence of pulmonary complications is the vari-
us grading systems and endpoints used. Whereas some
nvestigators defined the endpoint of their study as symp-
omatic pneumonitis and counted only those cases with
rade 1 pneumonitis that produced pulmonary symptoms
5, 6, 11, 28), others reported on the radiologic changes
ithout regard to the symptoms (7, 30). Another factor that
ay influence the findings is the prospective nature of a
tudy favoring the more frequent diagnosis of radiogenic
ung damage (3–8) compared with that in retrospective
rials (9–11, 28, 30). Whereas about one third of the patients
n our prospective study had developed radiographic
hanges by 3 months and 1 year after the radiotherapy, only
minority suffered from symptoms that were easily man-
ged, and none had respiratory problems 1 year after the
adiotherapy. Thus, in accord with the literature, we found
hat significant radiogenic lung sequelae after conformal
adiotherapy in breast cancer were rare.
We computed the risk of radiogenic lung damage in
elation to the age of the patient and the various data
eflecting the dose to the lung and found significant, al-
hough modest, increases connected with these parameters.
ge exerted the strongest effect on the risk of radiation lung
omplications. This finding is consistent with the results of
ther studies on breast cancer patients (5, 11, 14, 30). Using
he relative seriality model, Gagliardi et al. demonstrated
hat with the median age of their study population as a limit,
he dose to the lung that gives a complication probability
Table 5. OR and 95% CI for fibrosis with reg
Crude
Variable OR 95% CI
Age 1.06 1.02–1.10
MLD 1.10 1.02–1.10
V20 Gy* 1.04 1.01–1.06
D25%† 1.04 1.02–1.07
RTsupra–axilla‡ 2.02 0.92–4.46
Abbreviations: CI  confidence interval; M
For continuous variables, OR indicates the
* Volume of the ipsilateral lung receiving 2
† Dose to 25% of the volume of the ipsilate
‡ Irradiation of the supraclavicular and axillNormal Tissue Complication Probability) of 50% is 40.6 dy for patients 57 years and 26.9 Gy for patients 57
ears old (11). We tested whether use of the median age of
he study population as a threshold would better identify
atients at high risk for lung complications. Patients older
han the median (59.3  1.0 years) had risk of radiation
neumonitis and fibrosis that were approximately 2.5 and 3
imes higher, respectively. Moreover, above this age limit,
e demonstrated synergism between MLD, V20 Gy, D25%,
nd the age of the patient, indicating the need for heightened
ttention when radiotherapy is to be delivered to patients
ged over age 59. The elaboration of age-adjusted dose
onstraints on the basis of a large enough data set, devel-
ped by each institute according to its patient population,
ethods, and experience, is proposed.
The probability of lung complications may be improved
hrough the use of conformal radiotherapy (15, 16). A
idely studied predictor of the risk of radiogenic lung
amage is MLD, which was found to be the most accurate
redictor of radiation pneumonitis in the study by Seppen-
oolde et al. (25). In an analysis of 59 breast cancer
atients, the incidence of radiation pneumonitis greater than
rade 1 was around 10% at an MLD level of 20 Gy (9).
uidelines defining strict dose constraints for the conformal
adiotherapy of breast cancer are lacking. We used MLD
20 Gy as a dose constraint for the ipsilateral lung and
tudied the roles of V20 Gy and D25% in the prediction of
adiogenic lung sequelae. Strong correlations were found
etween these parameters, and all were related to the risk of
adiation lung damage.
Another parameter obviously related to radiogenic lung
amage is CLD (9, 10, 28). We kept CLD strictly 3 cm,
hich is probably why we did not find a significant effect of
LD on the risk of radiogenic lung complications. If 3D
onformal radiotherapy is applied, analysis of the parame-
ers reflecting the dose to or the volume of the irradiated
ung may predict radiation pneumonitis better than CLD,
lthough the latter is an excellent safety marker.
Inclusion of the lymph nodes in the irradiated volume
learly increases the radiation dose to the lung. Accord-
ngly, irradiation of the regional lymph nodes has been
age and the radiotherapy-related parameters
Adjusted for age
p OR 95% CI p
08
19 1.13 1.04–1.24 0.006
08 1.04 1.02–1.07 0.002
36 1.05 1.01–1.08 0.011
81 2.32 1.01–5.28 0.046
mean lung dose; OR  odds ratio.
r every one–unit increase in that variable.
g.
ph nodes.ard to
0.0
0.0
0.0
0.0
0.0
LD 
risk fo
0 Gy.
ral lunemonstrated in numerous studies to increase the risk of
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679Radiation lung sequelae in breast cancer patients ● Z. KAHÁN et al.adiation pneumonitis (3, 5, 7, 10, 28). Ooi et al. (7) ob-
erved a very high incidence of radiation pneumonitis, de-
erioration of the lung function indices, and the occurrence
f chest X-ray opacities following the delivery of locore-
ional radiotherapy in 30 breast cancer patients. In a study
f 121 breast cancer patients, symptomatic radiation pneu-
onitis developed exclusively in those who received lo-
oregional irradiation (5). We found that irradiation of the
xillary and the supraclavicular lymph node regions is as-
ociated with a 2.5-times higher risk of radiation pneumo-
itis and a twofold risk of radiogenic fibrosis.
We used two methods for the evaluation of radiogenic
ung changes on the CT scans. The quantitative assessment
f lung density changes provides information different from
hat yielded by inspection of the CT scans. Whereas the
ormer reflects the overall effect of radiation on the lung, the
atter reveals localized inflammatory or fibrotic changes that
ay be resulted by the overdosage in small lung volumes.
e modified the method of Wennberg et al. (5) for lung
ensity measurements because we believe our method pro-
ides more accurate data on the density changes of the
rradiated lung than the original for two reasons: first, lung
ensity variability related to breathing is corrected when the
ensity of the contralateral lung is included in the calcula-
ions; second, the performance of density assessments spe-
ifically in the irradiated lung region, which is especially
mall when conformal radiotherapy is delivered, makes the
ethod more sensitive and accurate than if the ventral third
f the lung volume is used for measurements, as described
n the original method. We suggest this improved method
or the quantitative analysis of small differences in lung
ensity after the adjuvant radiotherapy of breast cancer.
We found the lung density to be significantly lower 1 year
fter radiotherapy than after 3 months. Skoczylas et al. (12)
oted that, following radiotherapy, lung density underwent
n initial increase, then decreased, and then reached a stable
evel by 1 year in the majority of their early breast cancer
atients. Nonetheless, in a few patients, the lung changes
rogressed over years, without an initial early phase. In fact,
e also had three patients, without prior inflammatory ab-
ormalities, who developed de novo fibrotic changes 1 year
fter radiotherapy. Our observation is in agreement with the
heory that early and late radiogenic lung damage may
evelop independently (12, 13). It is a widely accepted
ractice to evaluate radiation fibrosis at 12 months (as a
inimum time interval) after the irradiation (7, 12, 30).
owever, because the lung changes may progress for even
–6 years, a longer follow-up is sometimes needed to
stablish the ultimate level of late lung damage (12).
We observed that the irradiation of the axillary and su-
raclavicular lymph nodes increased the risk of pneumonitis
nd fibrosis. Nonetheless, the MDCHC values reflecting the
nflammatory or fibrotic reaction of the irradiated apical
ung in those patients who received locoregional radiother-
py did not appear to be related to any clinical or dosimetric
arameters. Some clinical studies have demonstrated that
ecause of spatial differences in lung radiosensitivity, the Waudal lung regions are at higher risk of radiation pneumo-
itis than the cranial parts (14, 29). Although caution is
alled for because of the smaller number of patients with
upraclavicular irradiation, these results lead us to speculate
hat the independence of the MDCHC of the usual risk
actors in our study is an indicator of the reduced radiosen-
itivity of the apical lung parenchyma, compared with that
f other regions of the lung.
From an evaluation of the various NTCP models in a
arge group of breast cancer patients, Tsougos et al. (6)
oncluded that because the incidence of lung complications
s low, the variation of interpatient radiosensitivity plays a
ignificant role. Various efforts have been made to find
articular radiosensitivity indices (19–23, 29–33). TGF-,
multifunctional cytokine implicated in both tumor pro-
ression and normal tissue damage, has been studied as a
otential predictive marker of radiogenic sequelae in breast
ancer (19, 23) and lung cancer patients (21, 22, 31–33).
GF- is abundant, and its receptor is ubiquitously ex-
ressed in all tissues including various malignant tumors
18, 20). Among other biologic activities, TGF-, regulates
ifferentiation of fibroblasts, extracellular matrix produc-
ion, and angiogenesis (17, 18, 20). The expression of
GF- in normal tissues may be induced by chemotherapy
r radiotherapy (17, 18). The development of breast fibrosis
as found to be significantly related to the preradiotherapy
lasma TGF- level in breast cancer (23). Measurement of
he plasma TGF- levels after the delivery of 73.6 Gy to
ung cancer patients allowed the selection of those who
ould be treated beyond the conventional dose without the
isk of radiation complications (21, 22). Novakova-Jiresova
t al. (31) detected a trend to increased TGF- levels in lung
ancer patients who developed radiation pneumonitis by the
hird week of radiotherapy. The increase of TGF- was
orrelated with MLD (32) and V30 (33) in lung cancer
atients. We did not find TGF- to be a predictor of the risk
f early or late radiogenic lung changes. In fact, in patients
ith symptomatic pneumonitis, the TGF- level was ele-
ated 3 months after the radiotherapy, which should be
egarded as a consequence of the pneumonitis. The incon-
istency between our finding and that of others—that is, the
bsence of fluctuation in the plasma TGF- level, might be
xplained by the relatively small irradiated lung volumes in
ur patients. This explanation is supported by the recent
ndings of Evans et al. (33) showing that TGF- concen-
ration is generally not predictive for radiation pneumonitis
xcept when large lung volumes are irradiated.
The existence of an association between smoking and
adiation lung injury in breast cancer patients is controver-
ial (5, 14, 34, 35). Johansson et al. (35) and Theuws et al.
14) found lower incidence of radiation pneumonitis in
moking breast cancer patients (14, 35), malignant lym-
homa patients (14), and esophagus cancer patients (35)
ompared with nonsmokers. Similarly, postradiotherapy
ung inflammatory reactions were less intense in smoker
han in nonsmoker lung cancer patients (36). In contrast,ennberg et al. did not find significant differences in the
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adiotherapy according to the smoking habits of 118 breast
ancer patients (5). We observed significantly fewer cases
f pneumonitis among smokers than nonsmokers. Follow-
ng selection of the patients with symptomatic pneumonitis,
he difference was even larger. One explanation of our
ndings could be the immunosuppressive effects of ciga-
ette smoking and nicotine (37). In accord with the pub-
ished data (34), no effect of smoking on radiation fibrosis
as detected. Our findings extend the data on the relation of d
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